Filing Details

Accession Number:
0000950170-24-027243
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-06 16:43:53
Reporting Period:
2024-03-04
Accepted Time:
2024-03-06 16:43:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
949858 Achieve Life Sciences Inc. ACHV In Vitro & In Vivo Diagnostic Substances (2835) 954343413
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1477056 John Bencich 22722 29Th Dr Se
Suite 100
Bothell WA 98021
Ceo No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-03-04 10,000 $4.59 76,724 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Common Stock Warrants (right to buy) Acquisiton 2024-03-04 10,000 $0.00 10,000 $4.91
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
10,000 2024-03-04 No 4 P Direct
Footnotes
  1. The common shares reported on this Form 4 were purchased in a registered direct offering (the "RDO") at a price of $4.585, for an aggregate purchase price of $45,850 pursuant to a Securities Purchase Agreement (the "SPA") dated February 28, 2024. The SPA also provides for a concurrent private placement of warrants to purchase common shares (the "Private Placement Warrants") . The Private Placement Warrants are exercisable immediately upon issuance until the earlier of (x) three and one-half years after the date of issuance, and (y) 30 days following the Issuer's public disclosure of the acceptance of an NDA for cytisinicline by the FDA in a Day 74 Letter or equivalent correspondence.
  2. This number reflects a decrease of ownership of 6 shares of common stock from the number of shares previously reported due to an administrative error at the time of the Issuer's 1-for-20 split on July 31, 2020.